Double-blinded, randomised, placebo-controlled, multicentre , Phase IIa study to investigate the effect efficacy, safety and tolerability of phosphorylcholine human monoclonal antibody (PC-mAb) 3G10 on arterial inflammation, together with safety and tolerability, in subjects with elevated lipoprotein a (Lp[a ])

开始日期-

申办/合作机构

Athera Biotechnologies AB

NCT03991143 / Completed临床2期

A Phase IIa, Placebo-controlled, Double Blind, Randomised Multicentre Pilot Study to Investigate the Efficacy, Safety and Tolerability of the Monoclonal Antibody ATH3G10 in Patients With ST-elevation Myocardial Infarction

Patients with ST-segment elevation myocardial infarction (STEMI) that have suffered a major anterior wall infarction or where coronary blood flow is less than normal in spite of successful percutaneous coronary intervention (PCI) have a poor prognosis. There are today no medical treatments that specifically reduce risk in these patients. The acute inflammatory reaction in conjunction with a STEMI and reperfusion by PCI determines the final size of the infarction and the signals leading to left ventricular remodelling.
This study is designed to assess the efficacy and safety of single intravenous injection with ATH3G10, a fully human IgG1 antibody against phosphorylcholine, in high-risk subjects with STEMI. ATH3G10 aims to reduce inflammation and thereby infarction size and remodeling.

开始日期2019-03-29

申办/合作机构

Athera Biotechnologies AB

NCT03320265 / Terminated临床2期

Double-blind, Randomised, Placebo-controlled, Multicentre, Phase IIa Study to Investigate the Effect of PC-mAb on Arterial Inflammation in Subjects With Elevated Lipoprotein a

Inflammation and abnormal amount of lipids in the blood are key factors for the development and progression of atherosclerosis (thickening of the artery wall) and cardiovascular disease. Lipoprotein (a) is a pro-inflammatory plasma lipoprotein that is believed to be a risk factor for cardiovascular diseases. Vascular inflammation generates a range of effects, including endothelial dysfunction and migration of white blood cells into the vessel wall, which results in increased risk of cardiovascular events.
This study is designed to assess the effects of multiple monthly intravenous infusions with the fully human antibody called PC-mAb, in subjects with elevated lipoprotein (a).

开始日期2017-10-11

申办/合作机构

Athera Biotechnologies AB

100 项与 Phosphorylcholine monoclonal antibody (Athera Biotechnologies) 相关的临床结果

登录后查看更多信息

100 项与 Phosphorylcholine monoclonal antibody (Athera Biotechnologies) 相关的转化医学

登录后查看更多信息

100 项与 Phosphorylcholine monoclonal antibody (Athera Biotechnologies) 相关的专利（医药）

登录后查看更多信息

项与 Phosphorylcholine monoclonal antibody (Athera Biotechnologies) 相关的文献（医药）

2024-03-01·Environmental Research

A mechanistic approach to arsenic adsorption and immobilization in aqueous solution, groundwater, and contaminated paddy soil using pine-cone magnetic biochar

Article

作者: Mickan, Bede ; Ahmed Khan, Basit ; Ahmad, Mahtab ; Solaiman, Zakaria M ; Bolan, Nanthi ; Iqbal, Sajid ; Farooqi, Abida ; Siddique, Kadambot H M

Arsenic (As) poisoning in groundwater and rice paddy soil has increased globally, impacting human health and food security. There is an urgent need to deal with As-contaminated groundwater and soil. Biochar can be a useful remedy for toxic contaminants. This study explains the synthesis of pinecone-magnetic biochar (PC-MBC) by engineering the pinecone-pristine biochar with iron salts (FeCl₃.6H₂O and FeSO₄.7H₂O) to investigate its effects on As(V) adsorption and immobilization in water and soil, respectively. The results indicated that PC-MBC can remediate As(V)-contaminated water, with an adsorption capacity of 12.14 mg g^-1 in water. Isotherm and kinetic modeling showed that the adsorption mechanism involved multilayer, monolayer, and diffusional processes, with chemisorption operating as the primary interface between As(V) and biochar. Post-adsorption analysis of PC-MBC, using FTIR and XRD, further revealed chemical fixing and outer-sphere complexation between As(V) and Fe, O, NH, and OH as the main reasons for As(V) adsorption onto PC-MBC. Recycling of PC-MBC also had excellent adsorption even after several regeneration cycles. Similarly, PC-MBC successfully immobilized As in paddy soil. Single and sequential extraction results showed the transformation of mobile forms of As to a more stable form, confirmed by non-destructive analysis using SEM, EDX, and elemental dot mapping. Thus, Fe-modified pine-cone biochar could be a suitable and cheap adsorbent for As-contaminated water and soil.

2024-02-01·Auris Nasus Larynx

Application of phosphorylcholine derivative as mucosal adjuvant enhancing mucosal immune responses in the upper respiratory tract

Article

作者: Kurono, Yuichi ; Hirano, Takashi ; Yamashita, Masaru ; Jimura, Tomohiro ; Kawabata, Masaki

OBJECTIVEA phosphorylcholine (PC)-derivative with high binding ability (PCDB) was intranasally administered to mice with ovalbumin (OVA), and immune responses were investigated to determine whether PCDB has antigenicity and adjuvanticity.METHODSBALB/c mice were intranasally immunized with PCDB coupled with OVA, unbound PCDB plus OVA, cholera toxin (CT) plus OVA, OVA alone, and PCDB alone. Then, the production of OVA- and PC-specific antibodies in external secretions and serum, and the secretion of cytokines such as IL-4 and IFN-γ from splenic mononuclear cells by stimulation with PCDB and OVA were examined. Furthermore, the secretion of IL-12p40 from CD11c⁺ cells following stimulation with PCDB was observed to clarify the adjuvant effect of PCDB through TLR4.RESULTSIntranasal immunization with PCDB plus OVA increased OVA- and PC-specific IgA in external secretions and OVA- and PC-specific antibodies in the serum. The analysis of IgG subclasses specific to OVA and PC showed a higher production of IgG1 than IgG2, and the secretion of both IL-4 and IFN-γ was enhanced. However, IL-12p40 secretion from CD11c⁺ cells was increased and OVA-specific IgE production was not promoted by PCDB stimulation.CONCLUSIONIntranasal administration of the protein antigen with PCDB enhanced immune responses specific to the mixed antigen and PC. Although PCDB acted to bias the immune response toward the Th2-type, antigen-specific IgE production did not increase. These findings suggest that PCDB has the potential to be a mucosal vaccine with both adjuvanticity and antigenicity without causing side effects due to type I allergy.

2023-12-01·MethodsX

Nanophytosome formulation of β-1,3-glucan and Euglena gracilis extract for drug delivery applications

Article

作者: Palol, Varsha Virendra ; Chinnadurai, Raj Kumar ; Saravanan, Suresh Kumar ; Vuree, Sugunakar ; Subramanyam, Veni

Euglena gracilis (EG) is a unicellular freshwater alga known for its high β-1,3-glucan (BG) content with well-known biological properties and immune response. The high molecular weight structure of BG traditionally poses a challenge in terms of its size and absorption. Therefore, the aim of this study was to develop a novel drug delivery mechanism of BG and EG to nanophytosomes (NPs) by converting the heavy molecular weight of BG and EG into lipid phosphatidylcholine (PC), which plays an important role in improving their bioavailability and entrapment in captivity. The BG and EG NPs were developed by the solvent evaporation method while varying time and temperature to optimize their drug delivery ability. The size of BG-PC and EG-PC obtained by the Dynamic Light Scattering (DLS) method was 134.62 and 158.38 nm, respectively. Chemical (Fourier Transform Infra-Red) and structural (X-Ray Diffraction) characterization of NPs improved the binding capacity and the amorphous nature of both NPs. The shape of the NPs by Scanning electron microscopy (SEM) and Transmission electron microscopy (TEM) revealed their spherical, vesicular nature. The encapsulation efficiency of BG-PC and EG-PC was 82 ± 1.62 % and 87 ± 3.22 %, respectively, which improves the bioavailability. The developed methodology has thus proven effective in synthesizing BG-PC and EG-PC, which may be useful as NP drug delivery carriers. Future research could demonstrate the safety and effectiveness of long-term storage conditions for medical and pharmaceutical applications.•Nanophytosomes are tailored in size, shape and composition to optimize the delivery of phytochemicals/phytocompounds through nanoscale size and surface modification for better physiological absorption.•Nanophytosomes increase the stability of phytochemicals/phytocompounds and protect them from degradation due to heat or chemical reactions, leading to longer shelf life and improved therapeutic efficacy.•In this method, optimal conditions were created for the formation of β-1,3-glucan and Euglena gracilis extract nanophytosomes for successful development of drug delivery system that can effectively deliver bioactive compounds.

项与 Phosphorylcholine monoclonal antibody (Athera Biotechnologies) 相关的新闻（医药）

2024-03-21

·药通社

2024年，这些药品可能被集采（附清单）

2018年以来，国家医保局已组织开展九批国家组织药品集采，共纳入374种药品，平均每批国采纳入41个品种左右，第五批国采品种数量最多达到61个。故推测，第十批国采的化药品种数可能在41-61个。第九批中选和执行时间预计在今年3月执行，如果按此时间推算，第十批国采将在今年上半年开始。截至2024年2月26日，已经有120个品种满足“原研+过评”企业≥5家的竞争格局。第十批集采预测品种序号药品名称医保剂型规格过评+原研1磷酸西格列汀片口服常释剂型0.1g、25mg、50mg、100mg22+12地氯雷他定口服溶液口服液体剂0.5g：2.5mg、1g：5mg、100ml:50mg、10ml：5mg、120ml：60mg、150ml：75mg、30ml：15mg、50ml：25mg、60ml：30mg16+03苯甲酸阿格列汀片口服常释剂型12.5mg、25mg、6.25mg、12.5mg、25mg12+14哌柏西利胶囊口服常释剂型0.125g、0.1g、75mg、100mg、125mg11+15阿普米司特片口服常释剂型10mg、20mg、30mg10+16氨溴特罗口服溶液口服液体剂60ml：盐酸氨溴索90mg与盐酸克仑特罗60μg、100ml：盐酸氨溴索150mg与盐酸克仑特罗100μg、1ml：盐酸氨溴索1.5mg与盐酸克仑特罗1μg11+07氢溴酸伏硫西汀片口服常释剂型10mg、20mg、5mg10+18阿司匹林肠溶片口服常释剂型0.1g、0.3g、100mg9+19达格列净片口服常释剂型10mg、5mg9+110拉米夫定片口服常释剂型0.15g、0.1g、0.3g9+111沙库巴曲缬沙坦钠片口服常释剂型50mg（沙库巴曲24mg/缬沙坦26mg）、100mg（沙库巴曲49mg/缬沙坦51mg）、200mg（沙库巴曲97mg/缬沙坦103mg）9+112盐酸美金刚口服溶液口服液体剂100ml：1g、120ml：0.24g、50ml：0.5g9+013普瑞巴林口服溶液口服液体剂100ml：2g、200ml：4g、473ml：9.46g9+014碳酸司维拉姆片口服常释剂型0.8g8+115盐酸左西替利嗪口服滴剂口服液体剂10ml：50mg、15ml：75mg、20ml：0.1g、150ml：75mg、75ml：37.5mg9+016利格列汀片口服常释剂型5mg7+117索磷布韦片口服常释剂型0.4g7+118利培酮口服液口服液体剂0.001、30ml:30mg、0.1%(30ml:30mg)、0.1%(100mL:100mg)6+119磷酸特地唑胺片口服常释剂型0.2g5+120叶酸片口服常释剂型5mg6+021环孢素软胶囊口服常释剂型10mg、25mg、50mg、100mg4+122阿仑膦酸钠片口服常释剂型10mg、70mg4+123阿瑞匹坦胶囊口服常释剂型0.125g、80mg、120mg4+124艾曲泊帕乙醇胺片口服常释剂型25mg4+125艾司唑仑片口服常释剂型1mg、2mg5+026吡拉西坦片口服常释剂型0.4g、0.8g5+027丙戊酸钠口服溶液口服液体剂100ml：4g、300ml：12g4+128地诺孕素片口服常释剂型2mg4+129依帕司他片口服常释剂型50mg7+030艾地骨化醇软胶囊口服常释剂型0.5μg、0.75μg5+131重酒石酸卡巴拉汀胶囊口服常释剂型1.5mg、3mg、6mg5+132乙磺酸尼达尼布软胶囊口服常释剂型0.15g、0.1g6+033泊沙康唑肠溶片口服常释剂型0.1g5+134盐酸伐地那非片口服常释剂型5mg、10mg、20mg4+135酒石酸伐尼克兰片口服常释剂型0.5mg、1mg4+136盐酸非索非那定片口服常释剂型30mg、60mg、120mg、180mg4+137福多司坦口服溶液口服常释剂型100ml：8g、120ml：9.6g、500ml：40g、50ml：4g、5ml：0.4g5+038卡马西平片口服常释剂型0.1g、0.2g4+139口服补液盐散（Ⅲ）口服散剂5.125g5+040甲磺酸雷沙吉兰片口服常释剂型1mg4+141富马酸卢帕他定片口服常释剂型10mg4+142螺内酯片口服常释剂型0.1g、20mg、25mg5+043氯雷他定糖浆口服液体剂100ml：0.1g、1ml：1mg、60ml：60mg4+144瑞戈非尼片口服常释剂型40mg4+145替米沙坦氢氯噻嗪片口服常释剂型每片含替米沙坦40mg，氢氯噻嗪12.5mg、每片含替米沙坦80mg和氢氯噻嗪12.5mg4+146托伐普坦片口服常释剂型15mg、30mg5+047维生素B2片口服常释剂型5mg5+048硝酸甘油片口服常释剂型0.5mg5+049盐酸伊托必利片口服常释剂型50mg4+150左炔诺孕酮片口服常释剂型0.75mg、1.5mg4+151米拉贝隆缓释片缓释控释剂型25mg、50mg6+152枸橼酸托法替布缓释片缓释控释剂型11mg6+153左乙拉西坦缓释片缓释控释剂型0.5g、0.75g5+054曲伏前列素滴眼液滴眼剂0.4ml:16μg、2.5ml:0.1mg、2.5ml:0.075mg5+255溴芬酸钠滴眼液滴眼剂0.4ml:0.4mg、5ml:5mg6+156普拉洛芬滴眼液滴眼剂5ml：5mg4+157吸入用乙酰半胱氨酸溶液吸入剂3ml：0.3g11+158吸入用七氟烷吸入剂120ml、250ml6+259他克莫司软膏软膏剂10g:10mg、10g:3mg、0.1%(10g:10mg)、0.03%(10g:3mg)7+160乙酰半胱氨酸泡腾片其他0.6g5+161舒更葡糖钠注射液注射液2ml：0.2g、2ml：200mg、5ml：500mg16+162间苯三酚注射液注射液4ml：40mg14+063注射用哌拉西林钠注射剂0.5g、1g、2g、3g、4g13+064胞磷胆碱钠注射液注射剂2ml：0.1g、2ml：0.25g、4ml：0.5g10+065拉考沙胺注射液注射剂20ml：0.2g、10mg/ml9+166帕拉米韦注射液注射剂15ml：0.15g、20ml：0.2g、60ml：0.3g10+067泊沙康唑注射液注射剂16.7ml：0.3g9+168复方碳酸氢钠电解质注射液注射剂500ml、1000ml10+069注射用氨苄西林钠舒巴坦钠注射剂0.75g、1.5g、2.25g、3g7+170注射用氨苄西林钠舒巴坦钠注射剂0.5g、1g、2g8+071醋酸钠林格注射液注射剂500ml8+072氟尿嘧啶注射液注射剂10ml：0.25g、10ml：0.5g、20ml：1g8+073羟乙基淀粉130/0.4氯化钠注射液注射剂250ml:15g:2.25g、500ml:30g:4.5g、500ml:30g7+174氨茶碱注射液注射剂10ml:0.25g、0ml:0.25g、2ml:0.25、20ml:0.5g、2ml:0.5g、7+075氨基己酸注射液注射剂10ml:2g、20ml:4g、20ml:5g、8ml:2g7+076低钙腹膜透析液(乳酸盐-G1.5%）注射剂2000ml7+077低钙腹膜透析液(乳酸盐-G2.5%注射剂2000ml、2500ml7+078注射用拉氧头孢钠注射剂0.25g、0.5g、lg7+079注射用盐酸罗沙替丁醋酸酯注射剂75mg7+080乳酸钠林格注射液注射剂500ml6+081注射用醋酸西曲瑞克注射剂0.25ms5+182注射用右雷佐生注射剂0.25g、0.5g6+083硫酸阿米卡星注射液注射剂1ml：0.1g、2ml：0.2g5+084达肝素钠注射液注射剂0.2ml：2500IU、0.2ml：5000IU、0.3ml：7500IU、4+185注射用尼可地尔注射剂12mg、2mg、48mg7+086硫酸特布他林注射液注射剂1ml:0.5mg、5ml:2.5mg7+087地高辛注射液注射剂1ml:0.1mg、2ml:0.5mg、6+088乳酸环丙沙星氯化钠注射液注射剂100ml:0.2g、200ml:0.4g5+189左西孟旦注射液注射剂5ml:12.5mg5+190己酮可可碱注射液注射剂5ml:0.1g6+091卡前列素氨丁三醇注射液注射剂1ml:0.25mg5+192注射用青霉素钠注射剂100万IU、160万IU、400万IU、40万IU、500万IU、800万IU、80万IU6+093重酒石酸去甲肾上腺素注射液注射剂1ml:2mg、4ml:8mg6+094盐酸多巴酚丁胺注射液注射剂1.6ml：20mg、20ml：0.25g、40ml：0.5g、5ml：0.1g5+095盐酸多柔比星脂质体注射液注射剂10ml：20mg、25ml：50mg、5ml：10mg5+096注射用福多匹坦双葡甲胺注射剂0.15g5+097腹膜透析液（乳酸盐-G1.5%）注射剂2000ml5+098腹膜透析液（乳酸盐-G2.5%）注射剂2000ml5+099钆布醇注射液注射剂7.5ml：4.5354g、1:4.5354g、15ml：9.0708g4+1100盐酸格拉司琼注射液注射剂1ml：1mg、3ml：3mg5+0101重酒石酸间羟胺注射液注射剂1ml：10mg5+0102盐酸林可霉素注射液注射剂10ml：3g、2ml：0.6g5+0103氯化钾注射液注射剂10ml：1.5g、10ml：1g、20ml：3g5+0104盐酸纳洛酮注射液注射剂10ml：4mg、1ml：0.4mg、1ml：1mg、2ml：2mg5+0105盐酸曲马多注射液注射剂1ml：50mg、2ml：0.1g、2ml：50mg4+1106去氨加压素注射液注射剂1ml：13.35μg、1ml：15μg、1ml：3.56μg、1ml：4μg4+1107注射用头孢哌酮钠注射剂0.5g、1g、1.5g、2g、3g5+0108注射用头孢他啶阿维巴坦钠注射剂2.5g4+1109盐酸戊乙奎醚注射液注射剂1ml：0.5mg、1ml：1mg、2ml：2mg4+1110硝酸异山梨酯注射液注射剂10ml：10mg、5ml：5mg4+1111注射用亚胺培南西司他丁钠注射剂0.5g、1g4+1112小儿盐酸氨溴索滴剂口服液体剂50ml：0.75g15+0盐酸氨溴索滴剂20ml：0.3g、50ml：0.75g盐酸氨溴索口服溶液100ml：0.3g、100ml：0.6g、10ml：30mg、10ml：60mg、5ml：15mg、5ml：30mg113盐酸艾司洛尔注射液注射剂10ml：0.g、250ml：2.5g：1.475g12+0盐酸艾司洛尔氯化钠注射液100ml：2g：0.41g、50ml：1g：0.205g、2ml：0.2g114布洛芬混悬滴剂口服液体剂20ml：0.8g9+0布洛芬混悬液100ml：2g、30ml：0.6g115低钙腹膜透析液（乳酸盐-G1.35%）注射剂2000ml、2500ml9+0低钙腹膜透析液（乳酸盐-G4.25）2000ml腹膜透析液（乳酸盐）（低钙）2000ml116平衡盐溶液(供灌注用)外用液体剂250ml、500ml、7+1平衡盐冲洗液1000ml平衡盐眼内灌洗液15ml117西格列汀二甲双胍片口服常释剂型——6+1西格列汀二甲双胍片(I)磷酸西格列汀50mg(以游离碱计)和盐酸二甲双胍500mg西格列汀二甲双胍片(Ⅱ)磷酸西格列汀50mg(以游离碱计)和盐酸二甲双胍850mg、118盐酸安非他酮缓释片缓释控释剂型0.1g、0.15g、0.2g5+1盐酸安非他酮缓释片(Ⅱ)0.15g、0.3g119拉莫三嗪分散片口服常释剂型25mg、50mg5+1拉莫三嗪片0.1g、25mg、50mg、100mg120双氯芬酸钠缓释片缓释控释剂型0.1g、75mg5+0双氯芬酸钠缓释胶囊（Ⅰ）0.1g推荐阅读制剂/改良新药/立项/MAH/CXO/药品注册，报名get这场大会！↓

IPO

100 项与 Phosphorylcholine monoclonal antibody (Athera Biotechnologies) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
ST段抬高心肌梗死	临床2期	瑞典	Athera Biotechnologies AB	2019-03-29
心肌梗塞	临床2期	荷兰	Athera Biotechnologies AB	2019-03-26
动脉粥样硬化	临床2期	-	Dyax Corp.	-
冠状动脉再狭窄	临床2期	瑞典	Athera Biotechnologies AB	-
动脉炎	临床前	荷兰	Athera Biotechnologies AB	2017-10-11
动脉炎	临床前	瑞典	Athera Biotechnologies AB	2017-10-11

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ESC2018	N/A	-	-	PCmAb	鏇餘餘網蓋遞膚構鹹範(築選鑰觸繭醖糧齋觸鏇) = 獵觸鹹鬱壓糧齋鹽襯衊繭鑰蓋構遞簾艱鹽廠積 (蓋醖遞憲艱製醖廠襯鹹 )	-	2018-04-21